Vertex Q2 FY26 GAAP net income rises 6% to $1.1 billion; revenue increases 12% to $3.33 billion

• Vertex Q2 2026 revenue rose 12% to $3.33 billion from a year earlier; GAAP net income climbed to $1.1 billion.
• GAAP R&D expenses increased to $993.8 million; SG&A expenses rose to $582.2 million.
• CASGEVY revenue more than doubled year over year to $76 million; JOURNAVX revenue more than doubled to $50 million.
• Cash, cash equivalents and total marketable securities grew to $13.6 billion as of June 30, 2026.
• Raised 2026 revenue outlook to $13.1 billion-$13.2 billion; expects $500 million or more from non-CF products CASGEVY and JOURNAVX.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260803535433) on August 03, 2026, and is solely responsible for the information contained therein.